4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

Completed · Phase 2

Conditions studied: Epilepsy

In brief

The purpose of this study is to determine the safety of perampanel given as adjunctive, long-term treatment in patients with refractory partial onset seizures.

Key facts

Study ID

NCT00368472

Run by

Eisai Inc.

People needed

138

Starts

2006-10-01

Expected to finish

2014-07-01

Last updated by the study team

2015-12-10

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Phoenix, Arizona, United States
• Study site — Little Rock, Arkansas, United States
• Study site — Denver, Colorado, United States
• Study site — Bradenton, Florida, United States
• Study site — Melbourne, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Baltimore, Maryland, United States
• Study site — New Hyde Park, New York, United States
• Study site — Columbus, Ohio, United States
• Study site — West Jordan, Utah, United States
• Study site — Burlington, Vermont, United States
• Study site — Chatswood, New South Wales, Australia
• Study site — Maroochydore, Queensland, Australia
• Study site — Woodville, South Australia, Australia
• Study site — Edegem, Belgium
• Study site — Ghent, Belgium
• Study site — Leuven, Belgium
• Study site — Tielt, Belgium
• Study site — Brno, Czechia
• Study site — Hradec Králové, Czechia
• Study site — Olomouc, Czechia
• Study site — Ostrava, Czechia
• Study site — Prague, Czechia
• Study site — Rychnov nad Kněžnou, Czechia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.